Skip to main content


Fig. 5 | Clinical and Translational Medicine

Fig. 5

From: New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota

Fig. 5

Clinical applications of immune and metabolic checkpoint inhibitors and their limitations. Various metabolic checkpoint inhibitors (top yellow panel) and immune checkpoint inhibitors (bottom blue panel) are being targeted for cancer therapy. However, while metabolic checkpoint inhibitors lack specificity against tumors resulting in toxicity to host cells, immune checkpoint inhibitors are associated with immune-related adverse events and exacerbation of cancer progression in some cases

Back to article page